Journal
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 13, Issue 1, Pages 37-41Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2014.10.017
Keywords
Endoscopic Ultrasound Fine-Needle Aspiration; Malignant Cytology; Targeted Next-Generation Sequencing; Theranostics; Individualized Medicine
Categories
Funding
- Center for Individualized Medicine, Mayo Clinic, Rochester, MN [92541167, 925541166]
Ask authors/readers for more resources
Determination of tumor genetic architecture based on tissue analysis yields important information on signaling pathways involved in cancer pathogenesis and plays a growing role in choosing the optimal medical management of malignancies. Specifically, the advent of next-generation sequencing has led to a rapidly evolving era of relatively inexpensive, high-throughput DNA sequencing of tumors. One such example is multiplexed tumor genotyping (ie, panel testing) of more than 2800 mutations across 50 commonly mutated cancer-associated genes. This resulting mutational landscape shows medically actionable pathogenic alterations to optimize antitumor therapy. We recently assessed the performance and outcome of targeted next-generation sequencing with archived endoscopic ultrasound fine-needle aspirates across a broad range of primary and metastatic sites with encouraging accuracy. As a result, endoscopic ultrasound has the potential to move from a test for diagnosis or confirmation of malignancy, to one in which it could facilitate the personalization of cancer-directed therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available